Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis.

Watson NF, Ramage JM, Madjd Z, Spendlove I, Ellis IO, Scholefield JH, Durrant LG.

Int J Cancer. 2006 Jan 1;118(1):6-10.

2.

Natural killer cells infiltrating colorectal cancer and MHC class I expression.

Sandel MH, Speetjens FM, Menon AG, Albertsson PA, Basse PH, Hokland M, Nagelkerke JF, Tollenaar RA, van de Velde CJ, Kuppen PJ.

Mol Immunol. 2005 Feb;42(4):541-6.

PMID:
15607811
3.

Intratumoral T cell infiltration, MHC class I and STAT1 as biomarkers of good prognosis in colorectal cancer.

Simpson JA, Al-Attar A, Watson NF, Scholefield JH, Ilyas M, Durrant LG.

Gut. 2010 Jul;59(7):926-33. doi: 10.1136/gut.2009.194472.

PMID:
20581241
4.

Active immunosurveillance in the tumor microenvironment of colorectal cancer is associated with low frequency tumor budding and improved outcome.

Koelzer VH, Dawson H, Andersson E, Karamitopoulou E, Masucci GV, Lugli A, Zlobec I.

Transl Res. 2015 Aug;166(2):207-17. doi: 10.1016/j.trsl.2015.02.008. Epub 2015 Mar 4.

PMID:
25797890
5.

The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape.

Algarra I, García-Lora A, Cabrera T, Ruiz-Cabello F, Garrido F.

Cancer Immunol Immunother. 2004 Oct;53(10):904-10. Epub 2004 Apr 7. Review.

PMID:
15069585
6.

Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients.

Watson NF, Spendlove I, Madjd Z, McGilvray R, Green AR, Ellis IO, Scholefield JH, Durrant LG.

Int J Cancer. 2006 Mar 15;118(6):1445-52.

7.

The prognostic role of classical and nonclassical MHC class I expression in endometrial cancer.

Bijen CB, Bantema-Joppe EJ, de Jong RA, Leffers N, Mourits MJ, Eggink HF, van der Zee AG, Hollema H, de Bock GH, Nijman HW.

Int J Cancer. 2010 Mar 15;126(6):1417-27. doi: 10.1002/ijc.24852.

8.

Down-regulation of HLA-A expression correlates with a better prognosis in colorectal cancer patients.

Menon AG, Morreau H, Tollenaar RA, Alphenaar E, Van Puijenbroek M, Putter H, Janssen-Van Rhijn CM, Van De Velde CJ, Fleuren GJ, Kuppen PJ.

Lab Invest. 2002 Dec;82(12):1725-33.

PMID:
12480922
9.

Genome-wide differential genetic profiling characterizes colorectal cancers with genetic instability and specific routes to HLA class I loss and immune escape.

Bernal M, García-Alcalde F, Concha A, Cano C, Blanco A, Garrido F, Ruiz-Cabello F.

Cancer Immunol Immunother. 2012 Jun;61(6):803-16. doi: 10.1007/s00262-011-1147-7. Epub 2011 Nov 10.

PMID:
22072317
10.

Clinical significance of TROP2 expression in colorectal cancer.

Ohmachi T, Tanaka F, Mimori K, Inoue H, Yanaga K, Mori M.

Clin Cancer Res. 2006 May 15;12(10):3057-63.

11.

Tumor MHC class I expression improves the prognostic value of T-cell density in resected colorectal liver metastases.

Turcotte S, Katz SC, Shia J, Jarnagin WR, Kingham TP, Allen PJ, Fong Y, D'Angelica MI, DeMatteo RP.

Cancer Immunol Res. 2014 Jun;2(6):530-7. doi: 10.1158/2326-6066.CIR-13-0180. Epub 2014 Feb 20.

12.

Down-regulation of the antigen processing machinery is linked to a loss of inflammatory response in colorectal cancer.

Kasajima A, Sers C, Sasano H, Jöhrens K, Stenzinger A, Noske A, Buckendahl AC, Darb-Esfahani S, Müller BM, Budczies J, Lehman A, Dietel M, Denkert C, Weichert W.

Hum Pathol. 2010 Dec;41(12):1758-69. doi: 10.1016/j.humpath.2010.05.014.

PMID:
20869097
13.

Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project.

Rimsza LM, Roberts RA, Miller TP, Unger JM, LeBlanc M, Braziel RM, Weisenberger DD, Chan WC, Muller-Hermelink HK, Jaffe ES, Gascoyne RD, Campo E, Fuchs DA, Spier CM, Fisher RI, Delabie J, Rosenwald A, Staudt LM, Grogan TM.

Blood. 2004 Jun 1;103(11):4251-8. Epub 2004 Feb 19.

14.

Mechanisms of loss of HLA class I expression on colorectal tumor cells.

Browning M, Petronzelli F, Bicknell D, Krausa P, Rowan A, Tonks S, Murray N, Bodmer J, Bodmer W.

Tissue Antigens. 1996 May;47(5):364-71.

PMID:
8795136
16.

Human leukocyte antigen-E protein is overexpressed in primary human colorectal cancer.

Levy EM, Bianchini M, Von Euw EM, Barrio MM, Bravo AI, Furman D, Domenichini E, Macagno C, Pinsky V, Zucchini C, Valvassori L, Mordoh J.

Int J Oncol. 2008 Mar;32(3):633-41.

PMID:
18292941
17.

HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer.

Kikuchi E, Yamazaki K, Torigoe T, Cho Y, Miyamoto M, Oizumi S, Hommura F, Dosaka-Akita H, Nishimura M.

Cancer Sci. 2007 Sep;98(9):1424-30. Epub 2007 Jul 23.

18.

Distribution of HLA class I altered phenotypes in colorectal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21.

Maleno I, Cabrera CM, Cabrera T, Paco L, López-Nevot MA, Collado A, Ferrón A, Garrido F.

Immunogenetics. 2004 Jul;56(4):244-53. Epub 2004 Jul 16.

PMID:
15258706
19.

Natural killer cells play a role in MHC class I in vivo induction in tumor cells that are MHC negative in vitro.

Kijima M, Saio M, Oyang GF, Suwa T, Miyauchi R, Kojima Y, Imai H, Nakagawa J, Nonaka K, Umemura N, Nishimura T, Takami T.

Int J Oncol. 2005 Mar;26(3):679-84.

PMID:
15703823
20.

Microsatellite instability analysis in tumors with different mechanisms for total loss of HLA expression.

Jimenez P, Cantón J, Concha A, Cabrera T, Fernández M, Real LM, García A, Serrano A, Garrido F, Ruiz-Cabello F.

Cancer Immunol Immunother. 2000 Mar;48(12):684-90.

PMID:
10752476

Supplemental Content

Support Center